Skip to main content
Clinical Trials/NCT00970658
NCT00970658UnknownPhase 3

Clinical Multicenter Study, Randomized, Open, to Evaluate the Efficacy and Safety of Salonsip Compared to Sabiá Plaster Relief of the Signs and Symptoms in Patients With Contusions, Sprains, Injuries and Muscular Injuries With Less Than 24 Hours Early or Holders of Myalgia, Pain and Tendonitis in Regions Miofasciais Articulated.

Hisamitsu Farmaceutica do Brasil Ltda0 sites70 target enrollmentStarted: December 2009Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Sponsor
Enrollment
70
Primary Endpoint
Likert Scales and Visual Analogue Scales

Study Overview

Brief Summary

The purpose of this study is to evaluate the efficacy in reducing signs and symptoms in patients with contusions, sprains, muscular injuries and injuries with less than 24 hours early or holders of myalgia, pain and tendonitis in regions miofasciais articulated with Salonsip compared to Sabiá plaster.

It is clinical, open, multicenter, randomized, prospective and comparative, with patients entering at random.

Patients will be included in sufficient quantity to achieve the minimum number of 70 evaluable patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
12 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients of both sexes, of any race, aged 12 years;
  • Ability to read, understand and sign the Consent Form, in the case of children under age monitoring and consent of the person responsible;
  • Clinical diagnosis of bruises, sprains, trauma, muscle damage occurring in times less than 24 hours or myalgia, pain miofasciais or tendonitis.
  • Patients able to understand and maintain the clinical protocol

Exclusion Criteria

  • Known hypersensitivity to components of the formulas of both the product and the comparative test.
  • Known hypersensitivity to paracetamol.
  • Location of the lesion with skin wound or irritated.
  • Hepatic or renal diseases known.
  • Pregnant or breastfeeding.
  • Patients who require surgery or immobilization rigid;
  • Patients with fractures or rupture of the ligaments.
  • Patients in use of anticoagulants.
  • Patients with severe concomitant systemic diseases such as cancer, diabetes, congenital or acquired heart disease, hematological diseases, convulsive disorders, autoimmune diseases, renal failure, infections, hormonal disorders and pulmonary disorders.
  • History of alcoholism or use of illicit drugs;
  • Use of non-steroidal anti-inflammatory drugs, corticosteroids or venoterápicos, topics or any other form of administration.
  • Conditions which in the opinion of the investigator makes the patient unsuitable to participate in the study.

Arms & Interventions

Salonsip

Experimental

The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).

Intervention: Salonsip plaster (Drug)

Sabiá

Active Comparator

The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).

Intervention: Sabia plaster (Drug)

Outcomes

Primary Outcomes

Likert Scales and Visual Analogue Scales

Time Frame: two days

Secondary Outcomes

  • Safety evaluation by adverse events relate.(two days)

Investigators

Sponsor
Hisamitsu Farmaceutica do Brasil Ltda
Sponsor Class
Industry

Similar Trials